Fred Friedman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2530932/publications.pdf

Version: 2024-02-01

99	2,180	218677	265206
papers	citations	26 h-index	42 g-index

99	99	99	1307
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Identification of 2-Piperidone as a Biomarker of CYP2E1 Activity Through Metabolomic Phenotyping. Toxicological Sciences, 2013, 135, 37-47.	3.1	14
2	Two peptides derived from ras-p21 induce either phenotypic reversion or tumor cell necrosis of ras-transformed human cancer cells. Cancer Chemotherapy and Pharmacology, 2008, 62, 491-498.	2.3	5
3	The dual-specificity kinases, TOPK and DYRK1A, are critical for oocyte maturation induced by wild-type-but not by oncogenic- ras-p21 protein. Frontiers in Bioscience - Landmark, 2007, 12, 5089.	3.0	4
4	Rapid Conformational Dynamics of Cytochrome P450 2E1 in a Natural Biological Membrane Environmentâ€. Biochemistry, 2006, 45, 15617-15623.	2.5	5
5	PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growthin vivo. International Journal of Cancer, 2006, 119, 1577-1585.	5.1	31
6	Functional Interactions of Raf and MEK with Jun-N-Terminal Kinase (JNK) Result in a Positive Feedback Loop on the Oncogenic Ras Signaling Pathwayâ€. Biochemistry, 2005, 44, 10784-10795.	2.5	29
7	Molecular modeling of mammalian cytochrome P450s. Frontiers in Bioscience - Landmark, 2004, 9, 2796.	3.0	4
8	Comparison of Molecular Dynamics Averaged Structures for Complexes of Normal and Oncogenic ras-p21 with SOS Nucleotide Exchange Protein, Containing Computed Conformations for Three Crystallographically Undefined Domains, Suggests a Potential Role of These Domains in ras Signaling. Protein Journal, 2004, 23, 217-228.	1.6	3
9	Loop Domain Peptides from the SOS ras-Guanine Nucleotide Exchange Protein, Identified from Molecular Dynamics Calculations, Strongly Inhibit ras Signaling. Protein Journal, 2004, 23, 229-234.	1.6	3
10	An Effector Peptide from Glutathione-S-Transferase-pi Strongly and Selectively Blocks Mitotic Signaling by Oncogenic ras-p21. Protein Journal, 2004, 23, 235-238.	1.6	5
11	Peptides designed from molecular modeling studies of the ras -p21 protein induce phenotypic reversion of a pancreatic carcinoma cell line but have no effect on normal pancreatic acinar cell growth. Cancer Chemotherapy and Pharmacology, 2003, 52, 202-208.	2.3	16
12	Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site. Oncogene, 2003, 22, 1431-1444.	5.9	70
13	Arginine to lysine 108 substitution in recombinant CYP1A2 abolishes methoxyresorufin metabolism in lymphoblastoid cells. British Journal of Pharmacology, 2002, 136, 347-352.	5.4	14
14	Inhibition of ras-induced oocyte maturation by peptides from ras-p21 and GTPase activating protein (GAP) identified as being effector domains from molecular dynamics calculations. The Protein Journal, 2002, 21, 361-366.	1.1	6
15	Comparison of the average structures, from molecular dynamics, of complexes of GTPase activating protein (GAP) with oncogenic and wild-type ras-p21: identification of potential effector domains. The Protein Journal, 2002, 21, 349-359.	1.1	7
16	Identification of the site of inhibition of mitogenic signaling by oncogenic ras-p21 by a ras effector peptide. The Protein Journal, 2002, 21, 367-370.	1.1	8
17	Differences in Patterns of Activation of MAP Kinases Induced by Oncogenic rasâ€“p21 and Insulin in Oocytes. Experimental Cell Research, 2001, 269, 162-169.	2.6	18
18	Heme Pocket Disorder in Myoglobin:Â Reversal by Acid-Induced Soft Refoldingâ€. Biochemistry, 2001, 40, 11841-11850.	2.5	8

#	Article	IF	Citations
19	Plasmid expression of a peptide that selectively blocks oncogenic ras -p21-induced oocyte maturation. Cancer Chemotherapy and Pharmacology, 2001, 48, 9-14.	2.3	2
20	Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 12438-12443.	7.1	89
21	Synthetic peptide mimics of a predicted topographical interaction surface: the cytochrome P450 2B1 recognition domain for NADPH-cytochrome P450 reductase. The Protein Journal, 2000, 19, 23-32.	1.1	10
22	Identification, using molecular dynamics, of an effector domain of the ras-binding domain of the raf-p74 protein that is uniquely involved in oncogenic ras-p21 signaling. The Protein Journal, 2000, 19, 545-551.	1.1	3
23	Induction of oocyte maturation by jun -N-terminal kinase (JNK) on the oncogenic ras -p21 pathway is dependent on the raf -MEK-MAP kinase signal transduction pathway. Cancer Chemotherapy and Pharmacology, 2000, 45, 441-449.	2.3	27
24	Molecular modeling of mammalian cytochrome P450s. Cellular and Molecular Life Sciences, 2000, 57, 487-499.	5.4	26
25	ras-p21-Induced Cell Transformation: Unique Signal Transduction Pathways and Implications for the Design of New Chemotherapeutic Agents. Cancer Investigation, 2000, 18, 39-50.	1.3	28
26	Conformational Modulation of Human Cytochrome P450 2E1 by Ethanol and Other Substrates:Â A CO Flash Photolysis Study. Biochemistry, 2000, 39, 5731-5737.	2.5	24
27	The human peroxisome proliferator-activated receptor ?? gene: identification and functional characterization of two natural allelic variants. Pharmacogenetics and Genomics, 2000, 10, 321-333.	5.7	128
28	Molecular dynamics analysis of the structures of ras-guanine nucleotide exchange protein (SOS) bound to wild-type and oncogenic ras-p21. Identification of effector domains of SOS. The Protein Journal, 1999, 18, 867-874.	1.1	13
29	Identification of the site of inhibition of oncogenic ras-p21-induced signal transduction by a peptide from a ras effector domain. The Protein Journal, 1999, 18, 881-884.	1.1	10
30	Identification of a glutathione-S-transferase effector domain for inhibition of jun kinase, by molecular dynamics. The Protein Journal, 1999, 18, 859-866.	1.1	28
31	Inhibition of oncogenic and activated wild-type ras-p21 protein-induced oocyte maturation by peptides from the guanine-nucleotide exchange protein, SOS, identified from molecular dynamics calculations. Selective inhibition of oncogenic ras-p21. The Protein Journal, 1999, 18, 875-879.	1.1	10
32	Molecular modeling of cytochrome P450 2B1: mode of membrane insertion and substrate specificity. The Protein Journal, 1998, 17, 121-129.	1.1	32
33	Inhibition of human cytochrome P450 1A2 by flavones: A molecular modeling study. The Protein Journal, 1998, 17, 643-650.	1.1	31
34	Modification of Î±-Chain or Î²-Chain Heme Pocket Polarity by Val(E11) â†' Thr Substitution Has Different Effects on the Steric, Dynamic, and Functional Properties of Human Recombinant Hemoglobin. Journal of Biological Chemistry, 1997, 272, 26271-26278.	3.4	12
35	Assembly of Human Hemoglobin. Journal of Biological Chemistry, 1997, 272, 3478-3486.	3.4	13
36	Differential Mechanisms of Cytochrome P450 Inhibition and Activation by Î±-Naphthoflavone. Journal of Biological Chemistry, 1997, 272, 3149-3152.	3.4	117

#	Article	IF	Citations
37	Differential Interaction of Erythromycin with Cytochromes P450 3A1/2 in the Endoplasmic Reticulum:Â A CO Flash Photolysis Study. Biochemistry, 1997, 36, 3237-3241.	2.5	7
38	Drug-drug interactions: Effect of quinidine on nifedipine binding to human cytochrome P450 3A4. Biochemical Pharmacology, 1997, 53, 455-460.	4.4	51
39	Differential effects of flavonoids on testosterone-metabolizing cytochrome P450s. Life Sciences, 1997, 61, PL75-PL80.	4.3	17
40	Conformation-dependent phosphorylation of p53. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 1686-1691.	7.1	119
41	Molecular dynamics on complexes of ras-p21 and its inhibitor protein, rap-1A, bound to the ras-binding domain of the raf-p74 protein: identification of effector domains in the raf protein. The Protein Journal, 1997, 16, 619-629.	1.1	14
42	Inhibition of oncogenic and activated wild-type ras-p21 protein-induced oocyte maturation by peptides from the ras-binding domain of the raf-p74 protein, identified from molecular dynamics calculations. The Protein Journal, 1997, 16, 631-635.	1.1	22
43	Selective inhibition of oncogenic ras- p21 in vivo by agents that block its interaction with jun -N-kinase (JNK) and jun proteins. Implications for the design of selective chemotherapeutic agents. Cancer Chemotherapy and Pharmacology, 1997, 41, 79-85.	2.3	25
44	Interaction of Polycyclic Aromatic Hydrocarbons with Human Cytochrome P450 1A1: A CO Flash Photolysis Study. Archives of Biochemistry and Biophysics, 1996, 336, 261-267.	3.0	7
45	Cytochrome P450 conformation and substrate interactions as probed by CO binding kinetics. Biochimie, 1996, 78, 706-713.	2.6	48
46	Modulation of Human T-Lymphocyte Plasma Membrane Ca +2 Permeability by Imidazole Antimycotics. Immunopharmacology and Immunotoxicology, 1996, 18, 237-245.	2.4	9
47	Activation of c-Jun-NH2-Kinase by UV Irradiation Is Dependent on p21. Journal of Biological Chemistry, 1996, 271, 23304-23309.	3.4	61
48	Structural effects of the binding of GTP to the wild-type and oncogenic forms of theras-gene-encoded p21 proteins. The Protein Journal, 1995, 14, 721-730.	1.1	21
49	CO Binding Kinetics of Human Cytochrome P450 3A4. Journal of Biological Chemistry, 1995, 270, 5014-5018.	3.4	77
50	Interaction of Polycyclic Aromatic Hydrocarbons and Flavones with Cytochromes P450 in the Endoplasmic Reticulum: Effect on CO Binding Kinetics. Biochemistry, 1995, 34, 1942-1947.	2.5	10
51	Interaction between Cytochrome P450 2B1 and Cytochrome b5: Inhibition by Synthetic Peptides Indicates a Role for P450 Residues Lys-122 and Arg-125. Biochemical and Biophysical Research Communications, 1994, 201, 1090-1095.	2.1	29
52	Specificity of the cytochrome P-450 interaction with cytochromeb5. FEBS Letters, 1994, 346, 241-245.	2.8	17
53	Kinetics of CO Binding to Cytochromes P450 in the Endoplasmic Reticulum. Biochemistry, 1994, 33, 2484-2489.	2.5	17
54	Molecular Dynamics of the H-rasGene-Encoded p21 Protein; Identification of Flexible Regions and Possible Effector Domains. Journal of Biomolecular Structure and Dynamics, 1993, 11, 443-458.	3.5	16

#	Article	IF	Citations
55	Activated Conformations of theras-Gene-Encoded p21 Protein. 2. Comparison of the Computed and High-Resolution X-ray Crystallographic Structures of Gly-12 p21. Journal of Biomolecular Structure and Dynamics, 1993, 10, 905-918.	3.5	3
56	Dimerization specificity of myogenic helix-loop-helix DNA-binding factors directed by nonconserved hydrophilic residues.. Genes and Development, 1993, 7, 2456-2470.	5.9	54
57	Activated Conformations of theras-gene-Encoded p21 Protein. 1. An Energy-Refined Structure for the Normal p21 Protein Complexed with GDP. Journal of Biomolecular Structure and Dynamics, 1992, 9, 1025-1044.	3.5	7
58	A proteolytically sensitive region common to several rat liver cytochromes P450: effect of cleavage on substrate binding. Biochemistry, 1992, 31, 7155-7159.	2.5	11
59	A Flash Photolysis Instrument With Digital Smoothing of Data Using a Fast Fourier Transform. Instrumentation Science and Technology, 1992, 20, 213-221.	1.8	6
60	Cytochrome P 450-benzphetamine interactions in the endoplasmic reticulum: studies using a monoclonal antibody to P 450b. Biochemistry, 1992, 31, 8862-8867.	2.5	3
61	Evidence that oocyte maturation induced by an oncogenic ras-p21 protein and insulin is mediated by overlapping yet distinct mechanisms. Experimental Cell Research, 1992, 203, 329-335.	2.6	25
62	The effect of dilauroyl-l-3-phosphatidylcholine on the interaction between cytochromeP-450 1A1 and benzo[a]pyrene. FEBS Letters, 1992, 309, 249-252.	2.8	3
63	Correlation of the conformation of a modified ribonuclease octapeptide, homologous to peptide T, with its ability to induce CD4-dependent monocyte chemotaxis. The Protein Journal, 1992, 11, 475-481.	1.1	1
64	Prevention of 2-acetylaminofluorene-induced loss of nuclear envelope cytochrome P450 by the simultaneous administration of 3-methylcholanthrene. Biochemical Pharmacology, 1991, 41, 1331-1334.	4.4	2
65	A fluorescence study the interactions of benzo[a]pyrene, cytochrome P450c and NADPH-cytochrome P450 reductase. Biochemical Pharmacology, 1991, 42, 97-101.	4.4	10
66	Variation in Inducibility of Cytochrome P-450c and Aryl Hydrocarbon Hydroxylase in Rat Liver, Lung, Kidney, Pancreas and Nasopharynx. Pharmacology, 1990, 41, 256-262.	2.2	10
67	Developmental regulation of hepatic testosterone hydroxylases: Simultaneous activation and repression of constitutively expressed cytochromes P450 in senescent rats. Archives of Biochemistry and Biophysics, 1990, 277, 42-46.	3.0	16
68	Synthetic peptide antigens elicit monoclonal and polyclonal antibodies to cytochrome P450 IA2. Biochemical and Biophysical Research Communications, 1990, 169, 171-176.	2.1	8
69	Induction of rat liver microsomal and nuclear cytochrome p-450 by dietary 2-acetylaminofluorene and butylated hydroxytoluene. Biochemical Pharmacology, 1989, 38, 3075-3081.	4.4	11
70	Age-related changes in the iron spin state of testosterone-binding rat liver microsomal cytochromes P-450. Biochemical and Biophysical Research Communications, 1989, 158, 480-484.	2.1	3
71	Human Liver Cytochrome P-450 Related to a Rat Acetone-Inducible, Nitrosamine-Metabolizing Cytochrome P-450: Identification and Isolation. Pharmacology, 1989, 39, 137-144.	2.2	8
72	Studies on ethanol-inducible cytochrome P-450 in rabbit liver, lungs and kidneys. Biochemical Pharmacology, 1987, 36, 2689-2691.	4.4	18

#	Article	IF	Citations
73	Characterization of Human Fetal Hepatic Cytochrome P-450-Associated 7-Ethoxyresorufin O-Deethylase and Aryl Hydrocarbon Hydroxylase Activities by Monoclonal Antibodies. Developmental Pharmacology and Therapeutics, 1987, 10, 125-132.	0.2	27
74	MÃ¶ssbauer spectroscopic studies of hemoglobin and its isolated subunits. Biophysical Journal, 1986, 49, 1009-1015.	0.5	13
75	The effect of cigarette smoking on 7â€ethoxyresorufin Oâ€deethylase and other monooxygenase activities in human liver: analyses with monoclonal antibodies.. British Journal of Clinical Pharmacology, 1986, 22, 125-134.	2.4	86
76	Amino-terminal sequence and structure of monoclonal antibody-immunopurified cytochromes P 450. Biochemistry, 1986, 25, 2397-2402.	2.5	14
77	Epitope-relatedness and phenotyping of hepatic cytochromes P-450 with monoclonal antibodies. Biochemical Journal, 1985, 231, 671-676.	3.7	12
78	Flavone Modulators of Rat Hepatic Aryl Hydrocarbon Hydroxylase. Pharmacology, 1985, 31, 203-207.	2.2	17
79	Monoclonal antibody-directed radioimmunoassay detects cytochrome P-450 in human placenta and lymphocytes. Science, 1985, 228, 490-492.	12.6	67
80	Modulation of Rat Hepatic Aryl Hydrocarbon Hydroxylase by Various Flavones and Polycyclic Aromatic Hydrocarbons. Pharmacology, 1985, 31, 194-202.	2.2	9
81	THE APPLICATION OF MONOCLONAL ANTIBODIES FOR STUDIES ON CYTOCHROME P450. Drug Metabolism and Drug Interactions, 1985, 5, 159-192.	0.3	2
82	Specificity of Medicarpin and Related Isoflavonoids in Inhibition of Rat Hepatic Mixed Function Oxidase Activity. Pharmacology, 1985, 31, 289-293.	2.2	7
83	Preparation of catalytically active cytochromes P-450 by antigen exchange on monoclonal antibody based immunoadsorbents. Biochemistry, 1985, 24, 7044-7048.	2.5	3
84	Monoclonal antibody directed isolation and amino-terminal sequence analysis of phenobarbital induced rat liver cytochromes P-450. Biochemical and Biophysical Research Communications, 1985, 129, 926-933.	2.1	5
85	Catalytic activity of cytochromes P-450 purified by monoclonal antibody-directed immunopurification. Biochemical Pharmacology, 1985, 34, 2051-2054.	4.4	6
86	Monoclonal antibodies for studies on xenobiotic and endobiotic metabolism. Biochemical Pharmacology, 1985, 34, 2225-2234.	4.4	60
87	Monoclonal antibodies to cytochrome P-450 immunopurify a 45-kDa protein from a human lymphoblastoid cell line. FEBS Letters, 1985, 185, 67-70.	2.8	1
88	Phenotyping Cytochromes P450 with Monoclonal Antibodies. Toxicologic Pathology, 1984, 12, 155-161.	1.8	0
89	Preparation and Properties of Nickel Hemoglobin. Hemoglobin, 1984, 8, 47-60.	0.8	17
90	Amino-terminal sequence analysis of six cytochrome P-450 isozymes purified by monoclonal antibody directed immunopurification. Biochemical and Biophysical Research Communications, 1984, 123, 1201-1208.	2.1	27

#	Article	IF	Citations
91	Monoclonal antibody-directed immunopurification and identification of cytochromes P-450. Biochemical and Biophysical Research Communications, 1983, 116, 859-865.	2.1	32
92	The Solubility of Hemoglobins A and S Reconstituted with Various Metalloporphyrins. Hemoglobin, 1982, 6, 15-25.	0.8	7
93	The effect of cupric ion on the reoxidation pathway of an IgG1 immunoglobulin. Biochemical and Biophysical Research Communications, 1982, 109, 174-179.	2.1	1
94	Further studies of the riboflavin-binding immunoglobulin IgGGar. Resolution into fractions of different riboflavin content and aspects of reassembly. Biochemistry, 1981, 20, 2916-2921.	2.5	13
95	Further studies on the riboflavin-binding immunoglobulin IgGGar. Equilibrium and kinetic aspects of the interaction. Biochemistry, 1981, 20, 2922-2926.	2.5	9
96	An improved method for the preparation of renaturable apohemoglobin chains. Analytical Biochemistry, 1981, 117, 103-107.	2.4	8
97	Probes of Subunit Assembly and Reconstitution Pathways in Multisubunit Proteins. Annual Review of Biochemistry, 1979, 48, 217-250.	11.1	71
98	Acquisition of the covalent quaternary structure of an immunoglobulin G molecule. Reoxidative assembly in vitro. Biochemistry, 1977, 16, 2016-2025.	2.5	17
99	Stimulus-secretion coupling in platelets. Effects of drugs on secretion of adenosine 5'-triphosphate. Biochemistry, 1975, 14, 1315-1320.	2.5	30